J&J settles antipsychotics cases in historic $2.2B deal
By
Tim Mullaney
Dec 01, 2013
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes. The agreement...
Following Hurricane Sandy, drug makers get back to business
Nov 07, 2012
The typical long-term care resident requires eight or more medications daily. So with Hurricane Sandy ripping through the pharmaceutical corridor last week, many operators were rightfully concerned about...
J&J to pay $181 million for Risperdal settlement
By
McKnight's Staff
Aug 31, 2012
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.
J & J pays $158 million to settle Texas Medicaid fraud lawsuit
Jan 23, 2012
Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit. The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting...